Pre-made Lifastuzumab benchmark antibody ( Whole mAb ADC, anti-SLC34A2 therapeutic antibody, Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM Antibody) for drug discovery and mechanism of action (MOA) research
Cat No.: GMP-Bios-ab-311
Pre-Made Lifastuzumab biosimilar, Whole mAb ADC, Anti-SLC34A2 Antibody: Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Lifastuzumab vedotin, also known as DNIB0600A and RG-7599, is a novel antibody-drug conjugate being developed by Genentech/Roche, in clinical trials. The investigational drug is being compared to pegylated liposomal doxorubicin for the treatment of patients with platinum-resistant ovarian cancer.
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Pre-Made Lifastuzumab biosimilar, Whole mAb ADC, Anti-SLC34A2 Antibody: Anti-NAPI-3B/NAPI-IIb/NPTIIb/PULAM therapeutic antibody|
|Format||Whole mAb ADC|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||None|
|95-98% SI Structure||None|
|Conditions Discontinued||Fallopian tube cancer;Non-small cell lung cancer;Ovarian cancer;Peritoneal cancer|